TY - JOUR

T1 - MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

AU - Sastre-Garriga, Jaume

AU - Pareto, Deborah

AU - Battaglini, Marco

AU - Rocca, Maria A.

AU - Ciccarelli, Olga

AU - Enzinger, Christian

AU - Wuerfel, Jens

AU - Sormani, Maria P.

AU - Barkhof, Frederik

AU - Yousry, Tarek A.

AU - De Stefano, Nicola

AU - Tintoré, Mar

AU - Filippi, Massimo

AU - Gasperini, Claudio

AU - Kappos, Ludwig

AU - Río, Jordi

AU - Frederiksen, Jette

AU - Palace, Jackie

AU - Vrenken, Hugo

AU - Montalban, Xavier

AU - Rovira, Àlex

AU - on behalf of the MAGNIMS study group

PY - 2020

Y1 - 2020

N2 - Early evaluation of treatment response and prediction of disease evolution are key issues in the management of people with multiple sclerosis (MS). In the past 20 years, MRI has become the most useful paraclinical tool in both situations and is used clinically to assess the inflammatory component of the disease, particularly the presence and evolution of focal lesions — the pathological hallmark of MS. However, diffuse neurodegenerative processes that are at least partly independent of inflammatory mechanisms can develop early in people with MS and are closely related to disability. The effects of these neurodegenerative processes at a macroscopic level can be quantified by estimation of brain and spinal cord atrophy with MRI. MRI measurements of atrophy in MS have also been proposed as a complementary approach to lesion assessment to facilitate the prediction of clinical outcomes and to assess treatment responses. In this Consensus statement, the Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review the application of brain and spinal cord atrophy in clinical practice in the management of MS, considering the role of atrophy measures in prognosis and treatment monitoring and the barriers to clinical use of these measures. On the basis of this review, the group makes consensus statements and recommendations for future research.

AB - Early evaluation of treatment response and prediction of disease evolution are key issues in the management of people with multiple sclerosis (MS). In the past 20 years, MRI has become the most useful paraclinical tool in both situations and is used clinically to assess the inflammatory component of the disease, particularly the presence and evolution of focal lesions — the pathological hallmark of MS. However, diffuse neurodegenerative processes that are at least partly independent of inflammatory mechanisms can develop early in people with MS and are closely related to disability. The effects of these neurodegenerative processes at a macroscopic level can be quantified by estimation of brain and spinal cord atrophy with MRI. MRI measurements of atrophy in MS have also been proposed as a complementary approach to lesion assessment to facilitate the prediction of clinical outcomes and to assess treatment responses. In this Consensus statement, the Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review the application of brain and spinal cord atrophy in clinical practice in the management of MS, considering the role of atrophy measures in prognosis and treatment monitoring and the barriers to clinical use of these measures. On the basis of this review, the group makes consensus statements and recommendations for future research.

U2 - 10.1038/s41582-020-0314-x

DO - 10.1038/s41582-020-0314-x

M3 - Review

C2 - 32094485

AN - SCOPUS:85081061310

VL - 16

SP - 171

EP - 182

JO - Nature Reviews. Neurology

JF - Nature Reviews. Neurology

SN - 1759-4758

IS - 3

ER -